FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953921000> ?p ?o ?g. }

• W2953921000 endingPage "5182" @default.
• W2953921000 startingPage "5182" @default.
• W2953921000 abstract "Abstract Background - Acute myeloid leukemia (AML) in elderly patients (>65 years) is associated with poor prognosis with median overall survival (mOS) of 6 months. Hypomethylating agents (Azacytidine (Aza) and Decitabine) are used in elderly patients who are not candidates for intensive chemotherapy. Aza has resulted in complete remission/complete remission with incomplete hematologic recovery (CR/CRi) of 18-27.8% and mOS of 10.4-24.5 months. Decitabine resulted in CR/CRi of 18-47% and mOS of 7.7-8 months. We conducted a systemic review to assess survival benefit of novel combination drug regimens (CDR) involving hypomethylating agent (HMA) in elderly patients with newly diagnosed AML. Methods - Comprehensive literature search was conducted in Medline, Embase and Cochrane database. We included phase I/II studies only that used CDR involving HMA. Results - Initial database search (since inception) lead to 975 studies. After exclusion (duplicates, case reports, relapsed/refractory AML) final analysis included 17 studies(n=540) Ten phase I/II CDR studies involving Aza (n=334) were included. The various drugs used in combination included valproic acid/all trans retinoic acid (n= 42 ,CR/CRi=26.2% mOS= 18.1 m), thalidomide (n= 14,CR/CRi= 29%, mOS= 13.2 m ), gemtuzumab ozogamicin (GO) (n= 142,CR/CRi = 35-44%, mOS= 11 m), lenalidomide (n= 45,CR/CRi=28-44% , mOS= 3-8.2 m), panobinostat (n=38,CR/CRi=10-22.4%, mOS= 8 m), midostaurin (n=12,CR/CRi=25%, mOS=6 m) , entinostat (n=18 ,CR/CRi=0% ,mOS= 6 m ), Seven phase I/II CDR studies(n=206) involving decitabine were included. Drugs used in combination included low dose cytarabine and aclarubicin (n= 85 ,CR/CRi = 64.7% , mOS= 10-12 m ), tosedostat (n=17 ,CR/CRi= 59% mOS= 11.5 m ), bexarotene(n= 4 ,CR/CRi= 0% mOS= 9.2 m), valproic acid(n= 62 ,CR/CRi= 9% mOS= 7.4m) , GO (n= 40,CR/CRi= 45% , mOS= 7m ),bortezomib (n= 10,CR/CRi= 50% ), vorinostat(n = 31,CR/CRi= 30%). Seven studies reported outcomes for patients with adverse cytogenetics separately. Of these, Aza with lenalidomide (n= 11) had a mOS of 9.5 months and with panobinostat (n=12) the overall response rate was 25% and mOS of 7 months. Similarly, decitabine with vorinostat (n = 8) and tosedostat(n =12) resulted in CR/CRi of 25% and 43% respectively. Long term outcomes for these CDR with decitabine were not reported. In two additional studies, valproic acid/all trans retinoic acid given with AZA and low dose cytarabine & aclarubicin with decitabine(p=0.023) showed poor outcome through multivariable cox model analysis. Five studies reported response rates for subgroup of patients with secondary AML using HMA. Of these, Aza with lenalidomide (n= 16) had a CR/CRi = 27% with median response duration of 21.3 weeks, a CR/CRi of 0% with entinostat (n= 18) and CR/CRi of 22% with thalidomide(n=9). Decitabine given with tosadostat (n= 10) had CR/CRi of 60% and with bortezomib(n=3) the CR/CRi was 66%. The long term outcomes were not reported for these patients. Conclusion - Novel combinations involving Aza with valproic acid/all trans retinoic acid, thalidomide, or GO showed similar CR/CRi and mOS compared to Aza alone. Tosedostat, low dose cytarabine, and aclarubicin given in combination with decitabine showed best results with superior CR/CRi and mOS compared to decitabine alone. Bexarotene with decitabine also improved mOS over decitabine alone despite lower CR/CRi. In patients with adverse cytogenetics, Aza with lenalidomide or panobinostat showed superior CR/CRi and mOS. Decitabine given with vorinostat and tosedostat also showed superior CR/CRi. In patients with secondary AML, Aza in combination with lenalidomide or thalidomide and decitabine with tosedostat or bortezomib showed superior CR/CRi. These CDR for patients with adverse cytogenetics and secondary AML need further testing in studies designed with this specific patient population in which long term outcomes are also measured. These CDR need to be evaluated in large, randomized, prospective studies to assess definitive benefit. Disclosures No relevant conflicts of interest to declare." @default.
• W2953921000 created "2019-07-12" @default.
• W2953921000 creator A5005991606 @default.
• W2953921000 creator A5019625787 @default.
• W2953921000 creator A5020174810 @default.
• W2953921000 creator A5031094511 @default.
• W2953921000 creator A5069644314 @default.
• W2953921000 creator A5075881304 @default.
• W2953921000 creator A5087846949 @default.
• W2953921000 date "2018-11-29" @default.
• W2953921000 modified "2023-09-30" @default.
• W2953921000 title "Survival Benefit of Novel Drug Combinations Using Hypomethylating Agents for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Systemic Review" @default.
• W2953921000 doi "https://doi.org/10.1182/blood-2018-99-115810" @default.
• W2953921000 hasPublicationYear "2018" @default.
• W2953921000 type Work @default.
• W2953921000 sameAs 2953921000 @default.
• W2953921000 citedByCount "0" @default.
• W2953921000 crossrefType "journal-article" @default.
• W2953921000 hasAuthorship W2953921000A5005991606 @default.
• W2953921000 hasAuthorship W2953921000A5019625787 @default.
• W2953921000 hasAuthorship W2953921000A5020174810 @default.
• W2953921000 hasAuthorship W2953921000A5031094511 @default.
• W2953921000 hasAuthorship W2953921000A5069644314 @default.
• W2953921000 hasAuthorship W2953921000A5075881304 @default.
• W2953921000 hasAuthorship W2953921000A5087846949 @default.
• W2953921000 hasConcept C104317684 @default.
• W2953921000 hasConcept C126322002 @default.
• W2953921000 hasConcept C143998085 @default.
• W2953921000 hasConcept C150194340 @default.
• W2953921000 hasConcept C185592680 @default.
• W2953921000 hasConcept C190727270 @default.
• W2953921000 hasConcept C2776012956 @default.
• W2953921000 hasConcept C2776063141 @default.
• W2953921000 hasConcept C2776239401 @default.
• W2953921000 hasConcept C2776364478 @default.
• W2953921000 hasConcept C2776694085 @default.
• W2953921000 hasConcept C2777063308 @default.
• W2953921000 hasConcept C2778729363 @default.
• W2953921000 hasConcept C2778850193 @default.
• W2953921000 hasConcept C2779609412 @default.
• W2953921000 hasConcept C2780235182 @default.
• W2953921000 hasConcept C31760486 @default.
• W2953921000 hasConcept C55493867 @default.
• W2953921000 hasConcept C71924100 @default.
• W2953921000 hasConcept C90924648 @default.
• W2953921000 hasConceptScore W2953921000C104317684 @default.
• W2953921000 hasConceptScore W2953921000C126322002 @default.
• W2953921000 hasConceptScore W2953921000C143998085 @default.
• W2953921000 hasConceptScore W2953921000C150194340 @default.
• W2953921000 hasConceptScore W2953921000C185592680 @default.
• W2953921000 hasConceptScore W2953921000C190727270 @default.
• W2953921000 hasConceptScore W2953921000C2776012956 @default.
• W2953921000 hasConceptScore W2953921000C2776063141 @default.
• W2953921000 hasConceptScore W2953921000C2776239401 @default.
• W2953921000 hasConceptScore W2953921000C2776364478 @default.
• W2953921000 hasConceptScore W2953921000C2776694085 @default.
• W2953921000 hasConceptScore W2953921000C2777063308 @default.
• W2953921000 hasConceptScore W2953921000C2778729363 @default.
• W2953921000 hasConceptScore W2953921000C2778850193 @default.
• W2953921000 hasConceptScore W2953921000C2779609412 @default.
• W2953921000 hasConceptScore W2953921000C2780235182 @default.
• W2953921000 hasConceptScore W2953921000C31760486 @default.
• W2953921000 hasConceptScore W2953921000C55493867 @default.
• W2953921000 hasConceptScore W2953921000C71924100 @default.
• W2953921000 hasConceptScore W2953921000C90924648 @default.
• W2953921000 hasIssue "Supplement 1" @default.
• W2953921000 hasLocation W29539210001 @default.
• W2953921000 hasOpenAccess W2953921000 @default.
• W2953921000 hasPrimaryLocation W29539210001 @default.
• W2953921000 hasRelatedWork W1993118330 @default.
• W2953921000 hasRelatedWork W2042704711 @default.
• W2953921000 hasRelatedWork W2132191256 @default.
• W2953921000 hasRelatedWork W2299290565 @default.
• W2953921000 hasRelatedWork W2580530970 @default.
• W2953921000 hasRelatedWork W2625726302 @default.
• W2953921000 hasRelatedWork W2953921000 @default.
• W2953921000 hasRelatedWork W2980310053 @default.
• W2953921000 hasRelatedWork W2980857653 @default.
• W2953921000 hasRelatedWork W4307628892 @default.
• W2953921000 hasVolume "132" @default.
• W2953921000 isParatext "false" @default.
• W2953921000 isRetracted "false" @default.
• W2953921000 magId "2953921000" @default.
• W2953921000 workType "article" @default.